DB
TERN

Dmitry Balyasny’s Terns Pharmaceuticals TERN Stock Holding History

Dmitry Balyasny’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,779,445
Closed -$147M – 3489
2026
Q1 		$147M Buy
2,779,445
+1,887,542
+212% +$77.5M 0.19% 103
2025
Q4 		$36M Buy
+891,903
New +$20.6M 0.05% 463
2025
Q2 		– Sell
-127,887
Closed -$353K – 3338
2025
Q1 		$353K Buy
+127,887
New +$522K ﹤0.01% 2392
2024
Q3 		– Sell
-19,161
Closed -$130K – 3158
2024
Q2 		$130K Buy
+19,161
New +$116K ﹤0.01% 2387
2024
Q1 		– Sell
-13,854
Closed -$89.9K – 3110
2023
Q4 		$89.9K Buy
+13,854
New +$73.2K ﹤0.01% 2390
2023
Q3 		– Sell
-583,651
Closed -$5.11M – 2724
2023
Q2 		$5.11M Buy
583,651
+215,980
+59% +$2.52M 0.01% 1048
2023
Q1 		$4.35M Buy
+367,671
New +$3.51M 0.01% 1138
2021
Q3 		– Sell
-10,308
Closed -$126K – 2414
2021
Q2 		$126K Buy
+10,308
New +$176K ﹤0.01% 1776

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Dmitry Balyasny's TERN Position: Q2 2026 in Review

Dmitry Balyasny sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 2,779,445 shares — an estimated $147M sold.

Dmitry Balyasny first reported a position in TERN in Q2 2021 and held it in 8 quarters. The position peaked at $147M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Dmitry Balyasny reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 2,779,445 Terns Pharmaceuticals shares in Q2 2026, an estimated $147M.
  • Dmitry Balyasny first reported a position in Terns Pharmaceuticals in Q2 2021 and held it in 8 quarters.
  • Dmitry Balyasny's Terns Pharmaceuticals position peaked at $147M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.